Pancreatic cancer is a kind of digestive system tumor with extremely high malignancy. Its five-year survival rate is only about 10%, so it is called "the king of cancer". The reporter learned on the 18th that a research achievement of Yu Xianjun/Shi Si's team from the Pancreatic Surgery Department of the Affiliated Cancer Hospital of Fudan University has solved the "secret" of the new adjuvant treatment effect of the "cancer king": after pancreatic cancer patients received the new adjuvant treatment, pancreatic cancer changed from "cold" to "hot", from "sugar" to "fat"; The research team also found a mechanism that significantly improves the therapeutic effect of pancreatic cancer. The latest international authoritative academic journal "Cell Reports Medicine" has published this important research achievement in the form of a cover article. It is reported that surgery is the only radical treatment for pancreatic cancer, but the overall surgical effect is not satisfactory. Professor Yu Xianjun, Dean of the Affiliated Cancer Hospital of Fudan University and Pancreatic Surgery Department, said in an interview on the same day that in recent years, the anti-tumor treatment before surgery for pancreatic cancer, that is, preoperative neoadjuvant treatment, has been widely recognized and applied in the treatment of pancreatic cancer. From the perspective of treatment effectiveness, preoperative neoadjuvant therapy can downgrade the progression of pancreatic tumors and further improve the curative effect of surgery. "However, from the perspective of mechanism, there is still a lack of systematic research in the medical community on what changes the preoperative neoadjuvant therapy brings to pancreatic cancer and how these changes affect pancreatic cancer." Yu Xianjun said frankly. The research team found that after the new adjuvant treatment, the proportion of molecular subtypes of pancreatic cancer from "cold" to "hot", that is, "immune hot" increased significantly; The researchers also found that after the new adjuvant treatment, the status of pancreatic cancer changed from "sugar" to "fat". Associate Professor Shi Si, Pancreatic Surgery Department, Cancer Hospital Affiliated to Fudan University, said that this study revealed the mechanism of the efficacy of neoadjuvant therapy for pancreatic cancer, and provided a new strategy for neoadjuvant therapy for pancreatic cancer. Moreover, the research conclusions can be extended to more people such as advanced metastatic pancreatic cancer. It is revealed that the research team will carry out clinical trials in the future to verify the efficacy of relevant programs in patients with pancreatic cancer at different stages. (New News Agency)